 MINNEAPOLIS, Feb. 10, 2021 GLOBE NEWSWIRE -- Panbela Therapeutics, Inc. Nasdaq: PBLA, a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a research agreement with the Johns Hopkins University School of Medicine. The collaboration is intended to focus on the further development of Panbelas investigative agent SBP-101, including activity in cell lines outside of pancreatic cancer, biomarkers informing diagnostics and potential combination with checkpoint inhibitors. 